Invitrogen Jumps Into GPCR Tools Field Through Sentigen Buy; Will M&A Activity Pace Pick Up? | GenomeWeb
Building on its portfolio of kinase and ion channel drug screening products, Invitrogen said last week that it will acquire cell-based assay company Sentigen Holding for around $25.9 million in cash.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.